Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.
Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells.
Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving letrozole together with erlotinib may kill more tumor cells.
PURPOSE: This phase II clinical trial is studying how well giving letrozole together with
erlotinib works in treating postmenopausal women with estrogen receptor-positive and/or
progesterone receptor-positive locally recurrent or metastatic breast cancer.